Symbols / SGMT Stock $5.86 -0.17% Sagimet Biosciences Inc.

Healthcare • Biotechnology • United States • NGM
SGMT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. David A. Happel
Exch · Country NGM · United States
Market Cap 190.95M
Enterprise Value 77.90M
Income -51.04M
Sales —
FCF (ttm) -30.22M
Book/sh 3.42
Cash/sh 3.47
Employees 16
Insider 10d —
IPO Jul 14, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.07
PEG —
P/S —
P/B 1.71
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 22.18
Current Ratio 22.82
Debt/Eq 0.07
LT Debt/Eq —
EPS (ttm) -1.58
EPS next Y -1.91
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-11
ROA -25.70%
ROE -38.20%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 32.02M
Shs Float 29.98M
Insider Own 6.37%
Instit Own 45.01%
Short Float 12.10%
Short Ratio 9.33
Short Interest 3.60M
52W High 11.41
vs 52W High -48.64%
52W Low 3.03
vs 52W Low 93.40%
Beta 3.21
Impl. Vol. 12.50%
Rel Volume 0.49
Avg Volume 516.30K
Volume 252.13K
Target (mean) $25.78
Tgt Median $27.00
Tgt Low $8.00
Tgt High $35.00
# Analysts 9
Recom None
Prev Close $5.87
Price $5.86
Change -0.17%
About

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.78
Mean price target
2. Current target
$5.86
Latest analyst target
3. DCF / Fair value
$-16.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.86
Low
$8.00
High
$35.00
Mean
$25.78

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-11 reit HC Wainwright & Co. Buy → Buy $29
2026-02-03 init Guggenheim — → Buy $27
2026-02-03 reit HC Wainwright & Co. Buy → Buy $29
2026-01-28 init Barclays — → Equal-Weight $8
2025-11-14 main Citizens Market Outperform → Market Outperform $35
2025-10-22 init Clear Street — → Buy $29
2025-10-02 main Canaccord Genuity Buy → Buy $28
2025-08-11 init Wedbush — → Outperform $28
2025-07-24 init Canaccord Genuity — → Buy $28
2025-06-06 main Jones Trading Buy → Buy $27
2025-03-13 reit HC Wainwright & Co. Buy → Buy $32
2025-03-11 reit HC Wainwright & Co. Buy → Buy $32
2025-01-27 init Jones Trading — → Buy $42
2024-12-06 init Oppenheimer — → Outperform $30
2024-11-15 reit HC Wainwright & Co. Buy → Buy $32
2024-11-12 init UBS — → Buy $12
2024-10-31 reit HC Wainwright & Co. Buy → Buy $32
2024-10-02 reit HC Wainwright & Co. Buy → Buy $32
2024-08-15 main JMP Securities Market Outperform → Market Outperform $32
2024-08-15 reit HC Wainwright & Co. Buy → Buy $32
News
RSS: Latest SGMT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-19 MARTINS EDUARDO BRUNO Officer — 44,000 $0.00 $0
2026-02-19 CHAUCHE THIERRY Chief Financial Officer — 44,000 $0.00 $0
2026-02-19 ROZEK ELIZABETH Officer — 44,000 $0.00 $0
2026-02-19 HAPPEL DAVID Chief Executive Officer — 128,000 $0.00 $0
2026-02-10 MARTINS EDUARDO BRUNO Officer — 3,640 $5.36 $19,511
2026-02-10 CHAUCHE THIERRY Chief Financial Officer — 1,312 $5.36 $7,033
2026-02-10 ROZEK ELIZABETH Officer — 2,622 $5.36 $14,054
2026-02-10 HAPPEL DAVID Chief Executive Officer — 12,101 $5.36 $64,865
2025-11-20 KEMBLE GEORGE Officer and Director — 37,688 $7.69 $289,979
2025-11-04 ROZEK ELIZABETH Officer — 9,855 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
2.00
0.00
Operating Revenue
0.00
0.00
-100.00%
2.00
0.00
Operating Expense
56.89
+4.47%
54.45
+66.32%
32.74
+5.43%
31.05
Research And Development
39.05
+1.59%
38.44
+94.39%
19.78
-20.63%
24.92
Selling General And Administration
17.84
+11.40%
16.01
+23.51%
12.96
+111.26%
6.14
General And Administrative Expense
17.84
+11.40%
16.01
+23.51%
12.96
+111.26%
6.14
Other Gand A
17.84
+11.40%
16.01
+23.51%
12.96
+111.26%
6.14
Total Expenses
56.89
+4.47%
54.45
+66.32%
32.74
+5.43%
31.05
Operating Income
-56.89
-4.47%
-54.45
-77.14%
-30.74
+1.01%
-31.05
Total Operating Income As Reported
-56.89
-4.47%
-54.45
-77.14%
-30.74
+1.01%
-31.05
EBITDA
-56.89
-4.47%
-54.45
-77.14%
-30.74
+1.01%
-31.05
Normalized EBITDA
-56.89
-4.47%
-54.45
-77.12%
-30.74
+1.01%
-31.06
EBIT
-56.89
-4.47%
-54.45
-77.14%
-30.74
+1.01%
-31.05
Total Unusual Items
—
—
0.00
+33.33%
0.00
Total Unusual Items Excluding Goodwill
—
—
0.00
+33.33%
0.00
Net Income
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Pretax Income
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Net Non Operating Interest Income Expense
5.85
-34.16%
8.89
+210.73%
2.86
+417.18%
0.55
Net Interest Income
5.85
-34.16%
8.89
+210.73%
2.86
+417.18%
0.55
Interest Income Non Operating
5.85
-34.16%
8.89
+210.73%
2.86
+417.18%
0.55
Interest Income
5.85
-34.16%
8.89
+210.73%
2.86
+417.18%
0.55
Other Income Expense
—
—
0.00
+33.33%
0.00
Other Non Operating Income Expenses
—
—
—
0.00
Gain On Sale Of Security
—
—
0.00
+33.33%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Net Income From Continuing Operation Net Minority Interest
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Net Income From Continuing And Discontinued Operation
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Net Income Continuous Operations
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Normalized Income
-51.04
-12.01%
-45.57
-63.44%
-27.88
+8.60%
-30.50
Net Income Common Stockholders
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Diluted EPS
—
-1.45
+45.49%
-2.66
-93.39%
-1.38
Basic EPS
—
-1.45
+45.49%
-2.66
-93.39%
-1.38
Basic Average Shares
—
31.35
+199.71%
10.46
-52.83%
22.17
Diluted Average Shares
—
31.35
+199.71%
10.46
-52.83%
22.17
Diluted NI Availto Com Stockholders
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
116.48
-27.32%
160.26
+65.70%
96.72
+192.81%
33.03
Current Assets
116.40
-23.81%
152.77
+58.08%
96.65
+194.72%
32.79
Cash Cash Equivalents And Short Term Investments
113.12
-25.21%
151.25
+59.38%
94.90
+193.39%
32.34
Cash And Cash Equivalents
35.02
-53.82%
75.84
+0.93%
75.14
+47456.33%
0.16
Other Short Term Investments
78.10
+3.57%
75.41
+281.67%
19.76
-38.61%
32.19
Prepaid Assets
2.80
+163.81%
1.06
-21.52%
1.35
+227.36%
0.41
Current Deferred Assets
0.28
-7.84%
0.31
-5.26%
0.32
0.00
Other Current Assets
0.20
+26.75%
0.16
+112.16%
0.07
+117.65%
0.03
Total Non Current Assets
0.08
-98.96%
7.49
+10153.42%
0.07
-69.46%
0.24
Net PPE
0.08
+1.30%
0.08
+5.48%
0.07
-65.57%
0.21
Gross PPE
0.08
+1.30%
0.08
+5.48%
0.07
-65.57%
0.21
Other Properties
0.08
+1.30%
0.08
+5.48%
0.07
-65.57%
0.21
Investments And Advances
0.00
-100.00%
7.41
0.00
—
Non Current Prepaid Assets
—
—
0.00
-100.00%
0.03
Total Liabilities Net Minority Interest
5.10
+14.53%
4.45
-21.22%
5.65
-97.43%
219.98
Current Liabilities
5.10
+14.53%
4.45
-21.22%
5.65
+7.10%
5.28
Payables And Accrued Expenses
5.00
+14.30%
4.37
-18.39%
5.36
+5.25%
5.09
Payables
1.31
-8.14%
1.43
+666.13%
0.19
-83.47%
1.12
Accounts Payable
1.31
-8.14%
1.43
+666.13%
0.19
-83.47%
1.12
Current Accrued Expenses
3.69
+25.15%
2.95
-43.02%
5.17
+30.42%
3.96
Pensionand Other Post Retirement Benefit Plans Current
—
—
1.10
+73.74%
0.64
Current Debt And Capital Lease Obligation
0.08
+0.00%
0.08
+20.00%
0.07
-51.13%
0.13
Current Capital Lease Obligation
0.08
+0.00%
0.08
+20.00%
0.07
-51.13%
0.13
Other Current Liabilities
0.03
+440.00%
0.01
-97.85%
0.23
+308.77%
0.06
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
214.70
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.08
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.08
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
214.62
Stockholders Equity
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Common Stock Equity
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Capital Stock
0.00
+0.00%
0.00
+50.00%
0.00
+100.00%
0.00
Common Stock
0.00
+0.00%
0.00
+50.00%
0.00
+100.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
32.52
+1.01%
32.20
+40.62%
22.90
+3.26%
22.17
Ordinary Shares Number
32.52
+1.01%
32.20
+40.62%
22.90
+3.26%
22.17
Additional Paid In Capital
457.61
+1.49%
450.88
+32.31%
340.78
+873.62%
35.00
Retained Earnings
-346.35
-17.28%
-295.31
-18.25%
-249.74
-12.56%
-221.87
Gains Losses Not Affecting Retained Earnings
0.12
-47.83%
0.23
+666.67%
0.03
+135.71%
-0.08
Other Equity Adjustments
0.12
-47.83%
0.23
+666.67%
0.03
+135.71%
-0.08
Total Equity Gross Minority Interest
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Total Capitalization
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Working Capital
111.30
-24.96%
148.32
+63.00%
90.99
+230.72%
27.51
Invested Capital
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Total Debt
0.08
+0.00%
0.08
+20.00%
0.07
-69.19%
0.21
Capital Lease Obligations
0.08
+0.00%
0.08
+20.00%
0.07
-69.19%
0.21
Net Tangible Assets
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Tangible Book Value
111.38
-28.51%
155.81
+71.09%
91.06
+148.71%
-186.95
Available For Sale Securities
—
7.41
—
—
Derivative Product Liabilities
—
—
0.00
-100.00%
0.00
Investmentin Financial Assets
0.00
-100.00%
7.41
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-45.65
-7.58%
-42.44
-78.55%
-23.77
+2.96%
-24.49
Cash Flow From Continuing Operating Activities
-45.65
-7.58%
-42.44
-78.55%
-23.77
+2.96%
-24.49
Net Income From Continuing Operations
-51.04
-12.01%
-45.57
-63.46%
-27.88
+8.60%
-30.50
Other Non Cash Items
0.15
+4.14%
0.14
+4.32%
0.14
+6.92%
0.13
Stock Based Compensation
6.45
+21.96%
5.29
+5.97%
4.99
+165.43%
1.88
Asset Impairment Charge
0.23
0.00
—
—
Operating Gains Losses
—
—
-0.00
-33.33%
-0.00
Gain Loss On Investment Securities
—
—
-0.00
-33.33%
-0.00
Unrealized Gain Loss On Investment Securities
—
—
—
0.00
Change In Working Capital
-1.05
-0.48%
-1.05
-7.16%
-0.98
-123.21%
4.21
Change In Prepaid Assets
-1.83
-36500.00%
-0.01
+99.47%
-0.95
-166.30%
1.44
Change In Payables And Accrued Expense
0.93
+202.43%
-0.91
-855.83%
0.12
-95.88%
2.92
Change In Other Current Liabilities
-0.15
-11.76%
-0.14
+6.85%
-0.15
-6.57%
-0.14
Investing Cash Flow
4.56
+107.39%
-61.68
-590.33%
12.58
+139.30%
-32.01
Cash Flow From Continuing Investing Activities
4.56
+107.39%
-61.68
-590.33%
12.58
+139.30%
-32.01
Net Investment Purchase And Sale
4.56
+107.39%
-61.68
-590.33%
12.58
+139.30%
-32.01
Purchase Of Investment
-106.86
+1.13%
-108.09
-450.90%
-19.62
+52.66%
-41.45
Sale Of Investment
111.42
+140.11%
46.40
+44.11%
32.20
+241.25%
9.44
Financing Cash Flow
0.28
-99.74%
104.82
+21.65%
86.17
+118136.99%
-0.07
Cash Flow From Continuing Financing Activities
0.28
-99.74%
104.82
+21.65%
86.17
+118136.99%
-0.07
Net Common Stock Issuance
0.00
-100.00%
105.75
+17.92%
89.68
0.00
Proceeds From Stock Option Exercised
0.28
+141.23%
0.11
+1800.00%
0.01
-50.00%
0.01
Net Other Financing Charges
—
-1.04
+70.30%
-3.52
-4038.82%
-0.09
Changes In Cash
-40.82
-5922.97%
0.70
-99.07%
74.98
+232.54%
-56.57
Beginning Cash Position
75.84
+0.93%
75.14
+47456.33%
0.16
-99.72%
56.73
End Cash Position
35.02
-53.82%
75.84
+0.93%
75.14
+47456.33%
0.16
Free Cash Flow
-45.65
-7.58%
-42.44
-78.55%
-23.77
+2.96%
-24.49
Amortization Of Securities
-0.39
+68.95%
-1.25
-3286.49%
-0.04
+82.55%
-0.21
Common Stock Issuance
0.00
-100.00%
105.75
+17.92%
89.68
0.00
Issuance Of Capital Stock
0.00
-100.00%
105.75
+17.92%
89.68
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category